02/07/2025 Lynozyfic received accelerated approval from the US FDA for R/R Multiple Myeloma ( Ref ) Regeneron Pharmaceuticals announced...

01/07/2025 HanchorBio and Henlius signed a ~$200M licensing deal for HanchorBio's HCB101 ( Ref ) HanchorBio and Shanghai Henlius Biotech...

📢 AbbVie is set to acquire University of Pennsylvania ’s spinout, Capstan Therapeutics for up to $2.1 billion in cash, representing...

30/06/2025 Revolution Medicines and Summit entered into a clinical collaboration to evaluate RAS(ON) inhibitors and ivonescimab...

24/06/2025 CARsgen Therapeutics submitted a NDA for Satri-cel to China’s NMPA ( Ref ) CARsgen Therapeutics submitted the New Drug...

24/06/2025 Opdivo + Yervoy received supplemental approval in Japan to expand the use for unresectable hepatocellular carcinoma ( Ref )...

23/06/2025 Datroway has been approved in the US for locally advanced or metastatic EGFR-mutated NSCLC ( Ref ) The US FDA approved...

Highlights from the CHMP June 2025 Meeting are out! New Medicines 💊 Cordex Biologics ' (an ExCellThera company) dorocubicel...

22/06/2025 The Phase 3 STELLAR-303 trial of zanzalintinib + atezolizumab achieved significant OS benefit in metastatic colorectal cancer...

19/06/2025 Initial patient screening completed in Transgene's Phase 2 trial of TG4050 vaccine in resectable SCCHN ( Ref ) Transgene...

18/06/2025 The Phase 3 IDeate-Prostate01 trial of ifinatamab deruxtecan has been initiated in pretreated, metastatic CRPC patients ( Ref...

June 3rd Week , 2025 Regulatory Events 🎯 The US FDA approved the updated labelling of Pfizer ’s talazoparib (PARP inhibitor) +...

June 2nd Week, 2025 Regulatory Events 🎯 The US FDA approved Merck & Co./ MSD 's pembrolizumab (anti-PD-1) mono Q3W, 2Cy, as a...

May 5th Week, 2025 Regulatory Events 🎯 The EC approved Bristol Myers Squibb ’s subcutaneous nivolumab (Opdivo Quantig; anti-PD-1)...

May 3rd Week, 2025 Regulatory Events 🎯 Incyte and MacroGenics, Inc. ’s retifanlimab (anti-PD-1) + carboplatin + paclitaxel has been...

May 2nd Week, 2025 Special Designations ⭐ The US FDA granted the Fast Track designation to Adcentrx Therapeutics ’ ADRX-0706 (Nectin-4...

May 1st Week, 2025 Regulatory Events 🎯 Summit Therapeutics, Inc. and Akeso Biopharma ’s ivonescimab (PD-1 x VEGF BsAb) mono has...

April 4th Week, 2025 Regulatory & Market News 🎯 Akeso Biopharma ’s penpulimab-kcqx (anti-PD-1) + chemo received the US FDA approval for...

April 3rd Week, 2025 Regulatory Events 🎯 Bristol Myers Squibb ’s nivolumab (anti-PD-1) + ipilimumab (anti-CTLA-4) has been approved...

April 2nd Week, 2025 Regulatory Events 🎯 AstraZeneca and Daiichi Sankyo ’s trastuzumab deruxtecan (HER2 ADC) mono has been approved...